Table 6.

Genotypes and allele frequencies of ACE rs4646994, ATG rs699 and AGTR1 rs5186 polymorphisms in non-severe and severe COVID-19 patients

Polymorphisms	Genetic Models	Severe, n (%)	Non-severe, n (%)	Crude analysis		Adjusted analysisa
				OR (95% CI)	p	OR (95% CI)	p
ACE rs4646994	Codominant
	DD	84 (55.3)	60 (56.6)	1.00	–	1.00	–
	ID	58 (38.2)	31 (29.2)	1.33 (0.77–2.31)	0.18	1.12 (0.57–2.21)	0.42
	II	10 (6.6)	15 (14.2)	0.47 (0.20–1.13)	0.06	0.70 (0.14–3.45)	0.49
	Dominant
	DD	84 (55.3)	60 (56.6)	1.00	–	1.00	–
	ID + II	68 (44.7)	46 (43.4)	1.05 (0.64–1.74)	0.46	1.06 (0.55–2.05)	0.48
	Recessive
	DD + ID	142 (93.4)	91 (85.8)	1.00	–	1.00	–
	II	10 (6.6)	15 (14.2)	0.42 (0.18–0.99)	0.03	0.66 (0.13–3.19)	0.46
	Overdominant
	DD + II	94 (61.8)	75 (70.8)	1.00	–	1.00	–
	ID	58 (38.2)	31 (29.2)	1.49 (0.87–2.53)	0.08	1.16 (0.59–2.25)	0.39
	Alleles
	D	226 (74.5)	151 (75.0)	1.00	–	1.00	–
	I	78 (25.50)	61 (25.0)	0.85 (0.57–1.26)	0.24	0.99 (0.58–1.68)	0.54
ATG rs699	Codominant
	TT	8 (6.3)	12 (13.3)	1.00	–	1.00	–
	TC	119 (93.7)	78 (86.7)	2.28 (0.89–5.85)	0.06	2.33 (0.75–7.14)	0.11
	Alleles
	T	135 (53.15)	102 (56.67)	1.00	–	1.00	–
	C	119 (46.85)	78 (43.44)	1.15 (0.78–1.69)	0.26	1.16 (0.70–1.90)	0.31
ATGR1 rs5186	Codominant
	AA	96 (80.0)	58 (66.7)	1.00	–	1.00	–
	AC	23 (19.2)	26 (29.9)	0.53 (0.27–1.02)	0.06	0.55 (0.24–1.25)	0.11
	CC	1 (0.8%)	3 (3.5)	0.20 (0.02–1.98)	0.16	0.30 (0.01–4.97)	0.41
	Dominant
	AA	95 (80	58 (66.7)	1.00	–	1.00	–
	AC + CC	24 (20.0)	19 (35.3)	0.77 (0.38–1.52)	0.28	0.53 (0.23–1.18)	0.09
	Recessive
	AA + AC	119 (99.2)	84 (96.5)	1.00	–	1.00	–
	CC	1 (0.8)	3 (3.5)	23 (0.02–2.30)	0.20	0.34 (0.02–5.69)	0.45
	Overdominant
	AA + CC	97 (80.8)	61 (70.1)	1.00	–	1.00	–
	AC	23 (19.2)	26 (29.2)	0.55 (0.29–1.06)	0.052	0.56 (0.24–1.28)	0.12
	Alleles
	A	215 (89.58)	142 (81.61)	1.00	–
	C	25 (10.42)	32 (18.39)	0.51 (0.29–0.90)	0.01	0.56 (0.27–1.14)	0.08

^aAdjusted for age, sex, hypertension and diabetes